Alembic Pharmaceuticals is currently trading at Rs. 420.05, up by 1.15 points or 0.27% from its previous closing of Rs. 418.90 on the BSE.
The scrip opened at Rs. 419.65 and has touched a high and low of Rs. 420.10 and Rs. 417.50 respectively. So far 118 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 588.00 on 15-Feb-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 450.00 and Rs. 417.50 respectively. The current market cap of the company is Rs. 7870.54 crore.
The promoters holding in the company stood at 72.93%, while Institutions and Non-Institutions held 14.32% and 12.75% respectively.
In order to complete existing projects, Alembic Pharmaceuticals has earmarked a capital expenditure of Rs 720 crore for FY19. The company had spent about Rs 600 crore of capex in the last fiscal year.
The pharma firm has filed 12 ANDAs (abbreviated new drug applications) during the March quarter, taking the total filings in FY18 to 26.
The company has six formulation and three API manufacturing facilities. It manufactures general oral solids in Panelav near Vadodara, Gujarat, and is in the process of putting up oncology oral solids and oncology injectable facilities at the same location.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1659.60 |
| Dr. Reddys Lab | 1220.85 |
| Cipla | 1234.10 |
| Zydus Lifesciences | 930.85 |
| Lupin | 2309.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: